Triple agonist
How GLP-1 receptor agonists work — receptors, gastric emptying, and the satiety pathway.
Definition
A peptide that activates three different metabolic receptors simultaneously — typically GIP, GLP-1, and glucagon. Retatrutide is the first triple agonist in clinical development for weight loss. The glucagon component is hypothesized to add an energy-expenditure effect on top of GLP-1 and GIP appetite suppression.
Retatrutide: triple-agonist evidence →
Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.
Related terms in Mechanism
- GLP-1 receptor
- GIP receptor
- Dual agonist
- Gastric emptying
- Food noise
- Amylin
- GLP-1 tachyphylaxis
- Non-peptide GLP-1 agonist
- A1C (glycated hemoglobin)
- MASH / MASLD
- TBWL (Total Body Weight Loss)
- C-peptide
- eGFR (estimated glomerular filtration rate)
- Visceral adipose tissue (VAT)
- AHI (apnea-hypopnea index)
- SNAC (oral semaglutide absorption enhancer)
Looking for more depth?
- Retatrutide: triple-agonist evidence
- Browse the full GLP-1 glossary (124 terms across 8 categories)
- Research articles — primary-source deep dives
- Tools and calculators
- Compare GLP-1 telehealth providers